📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
92 announcements match the current filters (relevance ≥ 5).
Cerebra Integrated FY26 Net Loss Widens to ₹71.64 Cr; Auditor Issues Disclaimer of Opinion
Cerebra Integrated Technologies reported a catastrophic financial performance for FY26, with annual revenue collapsing by over 83% to ₹5.95 crore. The net loss widened to ₹71.64 crore from ₹47.32 crore in the previous year, exacerbated by a ₹9.76 crore inventory devaluation. Critically, the statutory auditors issued a 'Disclaimer of Opinion,' citing material uncertainties about the company's ability to continue as a going concern, ceased operations, and unconfirmed receivables exceeding ₹143 crore.
Key Highlights
Annual revenue plummeted 83.3% YoY to ₹5.95 crore in FY26 from ₹35.62 crore in FY25.
Statutory auditors issued a Disclaimer of Opinion, questioning the 'Going Concern' status due to significant operating losses and ceased refurbishment activities.
Trade receivables of ₹142.99 crore have been outstanding for more than one year, with ₹100.28 crore due from an overseas party overdue for over two years.
The company reported a standalone net loss of ₹71.64 crore for FY26, with an EPS of -₹6.40.
Auditors noted a lack of supporting documentation for a ₹9.76 crore ad-hoc inventory devaluation and ₹20.29 crore in long-term capital advances.
👀 What to Watch
Investors should exercise extreme caution as the auditor's disclaimer and 'going concern' warning suggest a high risk of insolvency. The massive unconfirmed receivables and lack of working capital indicate the company is in severe financial distress.
Bohra Industries Approves FY26 Audited Results; Reports Net Loss for the Year
Bohra Industries Limited's board met on May 29, 2026, to approve the audited financial results for the quarter and year ended March 31, 2026. The independent auditor's report indicates that the company incurred a net loss and other comprehensive losses during this period. To strengthen internal controls, the board appointed Jain Kothari & Co. as the Internal Auditor for the 2026-27 financial year. Despite the losses, the auditors provided an unmodified opinion, confirming the financial statements' accuracy.
Key Highlights
Board approved audited standalone financial results for the quarter and year ended March 31, 2026
The company reported a net loss for both the final quarter and the full financial year 2025-26
Jain Kothari & Co. appointed as Internal Auditor for FY 2026-27 to oversee audit and assurance
Auditors issued an unmodified opinion, though they noted the existence of net losses
👀 What to Watch
Given the reported net loss, investors should exercise caution and wait for the full balance sheet to assess liquidity and debt levels. Monitor the impact of the new internal auditor on financial oversight in the coming quarters.
Rainbow Children's Medicare Re-appoints CMD, Recommends ₹3.5 Dividend
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per share for FY26, with the record date set for July 21, 2026. The board has approved the re-appointment of founding promoter Dr. Ramesh Kancharla as CMD and Dr. Dinesh Kumar Chirla as Whole Time Director for five-year terms starting August 2026. Additionally, two independent directors have been re-appointed for a second five-year term, ensuring leadership continuity for the next half-decade. The company also confirmed the re-appointment of M/s. Lavanya & Associates LLP as cost auditors for the upcoming financial year.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (@35%) for the financial year ended March 31, 2026.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a 5-year term until August 2031.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term until August 2031.
Fixed July 21, 2026, as the record date for dividend payment and the 28th Annual General Meeting.
Approved re-appointment of two Independent Directors and the Cost Auditors for FY 2026-27.
👀 What to Watch
Investors should view the leadership continuity and dividend declaration as signs of stability and confidence in long-term growth. Monitor the detailed FY26 financial results to assess the company's operational efficiency and margin trends.
Rainbow Children's Re-appoints Top Leadership and Declares ₹3.5 Dividend
Rainbow Children's Medicare has announced the re-appointment of its core leadership team, including CMD Dr. Ramesh Kancharla and WTD Dr. Dinesh Kumar Chirla, for five-year terms starting August 2026. The board also recommended a final dividend of ₹3.5 per equity share for FY26, representing a 35% payout on face value. Additionally, two independent directors, including Ms. Sundari R. Pisupati, were re-appointed for second five-year terms to ensure governance stability. These moves signal strong management continuity for the specialized pediatric healthcare provider through 2031.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY2025-26
Re-appointed Dr. Ramesh Kancharla as CMD for a 5-year term from August 11, 2026, to August 10, 2031
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term starting August 2026
Fixed July 21, 2026, as the Record Date for dividend eligibility and the 28th AGM
Re-appointed Independent Directors Santanu Mukherjee and Sundari R. Pisupati for second 5-year terms
👀 What to Watch
Investors should take confidence in the management continuity and the company's commitment to shareholder returns via dividends. Monitor the upcoming AGM on July 29, 2026, for further strategic updates.
Rainbow Children's Medicare Approves ₹3.5 Dividend and Re-appoints Key Management
Rainbow Children's Medicare has announced its audited financial results for FY26 along with a final dividend of ₹3.5 per share, representing 35% of the face value. The board has approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term starting August 2026. Additionally, several key board members, including Dr. Dinesh Kumar Chirla and two independent directors, have been re-appointed for five-year terms to ensure leadership continuity. The record date for the dividend and the 28th Annual General Meeting is set for July 21, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% on FV of ₹10) for FY 2025-26
Re-appointed Dr. Ramesh Kancharla as CMD for a 5-year term from August 11, 2026, to August 10, 2031
Fixed July 21, 2026, as the record date for dividend payment and the 28th AGM
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term
Approved re-appointment of Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati for second 5-year terms
👀 What to Watch
Investors should note the dividend record date of July 21, 2026, to ensure eligibility for the ₹3.5 payout. The continuity in top leadership is a positive signal for long-term stability and execution of the company's expansion plans.
Rainbow Children's Medicare Re-appoints Top Management; Recommends ₹3.5 Dividend
Rainbow Children's Medicare has approved the re-appointment of its core leadership, including CMD Dr. Ramesh Kancharla and WTD Dr. Dinesh Kumar Chirla, for five-year terms starting August 2026. The board also recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY26, with a record date set for July 21, 2026. These leadership extensions ensure management continuity for the specialized pediatric healthcare provider through 2031. Additionally, the company confirmed audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Re-appointment of Dr. Ramesh Kancharla as CMD for a 5-year term until August 2031
Re-appointment of Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term
Recommended a final dividend of ₹3.5 per share on a face value of ₹10
Record date for dividend eligibility and AGM fixed as July 21, 2026
Re-appointment of two Independent Directors for second 5-year terms to ensure board stability
👀 What to Watch
Investors should welcome the management continuity as it ensures the execution of long-term growth strategies. Those seeking the ₹3.5 dividend should ensure they hold shares before the July 21 record date.
Rainbow Children's Medicare Re-appoints CMD; Recommends ₹3.5 Final Dividend for FY26
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per share for FY26, with the record date fixed for July 21, 2026. The Board approved the re-appointment of founding promoter Dr. Ramesh Kancharla as Chairman & Managing Director for a five-year term starting August 11, 2026. Leadership continuity is further strengthened by the re-appointment of Dr. Dinesh Kumar Chirla as Whole Time Director and two independent directors for five-year terms. The company also confirmed audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for the financial year ended March 31, 2026.
Re-appointed Dr. Ramesh Kancharla as CMD for a five-year term from August 11, 2026, to August 10, 2031.
Fixed July 21, 2026, as the record date for dividend eligibility and the 28th Annual General Meeting.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a five-year term starting August 2026.
Statutory auditors S.R. Batliboi & Associates LLP issued an unmodified opinion on the FY26 audited financial results.
👀 What to Watch
Investors should benefit from the dividend payout and the stability offered by the long-term re-appointment of the core management team. Review the detailed FY26 financial results to assess the company's operational growth and expansion progress.
Rainbow Children's Medicare FY26: Network Grows to 24 Hospitals with 2,435 Bed Capacity
Rainbow Children's Medicare Limited (RCML) reported strong operational growth for FY26, expanding its network to 24 hospitals and 1,050+ doctors. The company recorded over 1.59 million outpatient visits and 104,000 inpatient admissions, supported by a total capacity of 2,435 beds. Key growth drivers included the acquisition of hospitals in Warangal and Guwahati, plus new facilities in Bengaluru. The hub-and-spoke model remains central to their strategy, optimizing tertiary and quaternary pediatric care delivery.
Key Highlights
Network expanded to 24 hospitals across 9 cities with a total capacity of 2,435 beds.
Achieved 1.59 million+ outpatient visits and 104,000+ inpatient admissions in FY26.
Facilitated 19,000+ deliveries, reinforcing leadership in integrated perinatal and pediatric care.
Executed strategic acquisitions of Prashanthi Hospital (Warangal) and Pratiksha Hospital (Guwahati).
Strong clinical foundation with 1,050+ full-time doctors and 3 JCI-accredited facilities.
👀 What to Watch
Investors should maintain a positive outlook as the company successfully integrates new acquisitions and scales its hub-and-spoke model. Monitor the operational ramp-up of new hospitals in Bengaluru and Guwahati for future revenue growth.
Rainbow Children's Q4 PAT Surges 38.3% YoY to ₹782 Mn; Declares ₹3.5 Dividend
Rainbow Children's Medicare reported a strong Q4 FY26 with revenue growing 24.3% YoY to ₹4,599 Mn and PAT increasing by 38.3% to ₹782 Mn. The company successfully expanded its bed capacity by 23% YoY to 2,375 beds, while maintaining a healthy ARPOB of ₹62,464. Management indicated that the current phase of major capacity addition is complete, shifting focus to occupancy ramp-up and operational efficiency. A final dividend of ₹3.5 per share was recommended, supported by a robust cash position of ₹5,942 Mn.
Key Highlights
Q4 Revenue grew 24.3% YoY to ₹4,599 Mn, while PAT jumped 38.3% to ₹782 Mn.
EBITDA margins improved by 47 bps YoY to 31.5% in Q4 FY26.
Operational beds increased 19% YoY to 1,806, though occupancy slightly dipped to 45.3% due to new capacity.
ARPOB (Average Revenue Per Occupied Bed) saw a healthy 8% YoY growth to ₹62,464.
Board recommended a final dividend of ₹3.5 per equity share (35% of face value).
👀 What to Watch
Investors should monitor the occupancy ramp-up in the newly added Bengaluru and regional facilities as the company shifts from expansion to execution. The strong cash reserves of ₹5,942 Mn and internal accruals provide a solid foundation for completing planned projects in Gurugram and Pune without external debt.
Rainbow Children's Medicare Recommends ₹3.5 Dividend; Sets July 21 as Record Date
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per equity share (35% of face value) for the financial year ended March 31, 2026. The company has fixed July 21, 2026, as the record date to determine eligibility for the dividend and the upcoming 28th Annual General Meeting. In a move to ensure leadership continuity, the Board also approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term. The financial results for FY26 were approved with an unmodified audit opinion from S.R. Batliboi & Associates LLP.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share on a face value of ₹10 for FY2025-26
Fixed Tuesday, July 21, 2026, as the Record Date for dividend payment and AGM eligibility
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for 5 years until August 2031
Scheduled the 28th Annual General Meeting for Wednesday, July 29, 2026
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026
👀 What to Watch
Investors seeking the ₹3.5 dividend should ensure they hold the stock before the July 21 record date. The five-year extension for the founding leadership is a positive sign for long-term strategic stability.
Rainbow Children's Medicare Recommends ₹3.5 Dividend and Re-appoints Key Management
Rainbow Children's Medicare has recommended a final dividend of ₹3.5 per equity share for the financial year ended March 31, 2026. The board also approved the audited financial results for FY26 with an unmodified audit opinion, signaling financial transparency. Leadership stability is a key takeaway as the board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and MD for a further five-year term. The company has scheduled its 28th AGM for July 29, 2026, and set the dividend record date for July 21, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Fixed July 21, 2026, as the record date for dividend payment and AGM attendance.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a 5-year term until 2031.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a 5-year term.
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the July 21, 2026 record date. The long-term re-appointment of the core management team is a positive sign for strategic continuity.
Rainbow Children's Medicare Recommends ₹3.5 Dividend and Re-appoints Top Management
Rainbow Children's Medicare has approved its audited financial results for the fiscal year ended March 31, 2026, receiving a clean audit opinion from S.R. Batliboi & Associates. The board recommended a final dividend of ₹3.5 per equity share, representing 35% of the face value. Significant management continuity was established with the re-appointment of the Chairman and Managing Director, along with other key directors, for five-year terms. The record date for the dividend is set for July 21, 2026, with the Annual General Meeting scheduled for July 29, 2026.
Key Highlights
Recommended a final dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term until 2031.
Fixed July 21, 2026, as the record date for dividend payment and AGM attendance.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results.
Re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a five-year term starting August 2026.
👀 What to Watch
Investors should ensure they hold shares by the record date of July 21, 2026, to qualify for the ₹3.5 dividend. The long-term re-appointment of the founding management team provides positive visibility on leadership stability.
Indian Terrain Q4 FY26 Revenue Up 19% to ₹106.5 Cr; EBITDA Surges 160% with PBT Turnaround
Indian Terrain Fashions reported a strong operational recovery in Q4 FY26, with revenue growing 19% YoY to ₹106.53 crore. The company achieved a significant turnaround in Profit Before Tax (PBT), posting ₹3.54 crore against a loss of ₹3.84 crore in the previous year. EBITDA margins more than doubled to 11.28%, driven by disciplined discounting and an improved channel mix. Although the company reported a marginal PAT loss of ₹0.90 crore, it represents a 58.6% improvement YoY, signaling a clear path toward sustainable profitability.
Key Highlights
Revenue from operations increased 19% YoY to ₹106.53 crore in Q4 FY26.
EBITDA surged 160.35% to ₹12.02 crore with margins expanding from 5.16% to 11.28% YoY.
Profit Before Tax (PBT) turned positive at ₹3.54 crore compared to a loss of ₹3.84 crore in Q4 FY25.
Net loss (PAT) narrowed significantly to ₹0.90 crore from a loss of ₹2.17 crore in the previous year.
Strategic shift towards MBO and franchise channels improved scalability and reduced dependence on EBO-led growth.
👀 What to Watch
The operational turnaround and PBT positivity suggest the company's cost-control and channel-mix strategies are yielding results. Investors should monitor the transition to consistent PAT positivity and sustained margin improvement in the upcoming fiscal year.
Indian Terrain Reports Q4 FY26 Turnaround with 160% EBITDA Growth and Positive PBT
Indian Terrain Fashions Limited achieved a significant financial turnaround in FY26, reporting a Profit Before Tax (PBT) of ₹2.71 Cr compared to a loss of ₹41.01 Cr in the previous year. Q4 revenue grew by 19% YoY to ₹106.53 Cr, driven by a robust 61% growth in the Multi-Brand Outlet (MBO) channel. The company's EBITDA for the full year reached ₹36.43 Cr, marking a sharp recovery from an operating loss in FY25. Management's focus on an asset-light distribution model and inventory optimization has successfully improved gross margins by 442 basis points for the full year.
Key Highlights
Full-year FY26 revenue increased 11% to ₹377.67 Cr from ₹340.60 Cr in FY25
Achieved a turnaround in PBT to ₹2.71 Cr in FY26 from a massive loss of ₹41.01 Cr in FY25
EBITDA for Q4 FY26 surged 160% YoY to ₹12.02 Cr, with margins expanding to 11.28%
MBO channel emerged as a primary growth engine, contributing ₹112.38 Cr in FY26, up 86% YoY
Gross Margin improved by 442 bps for the full year to 42.18% due to better channel mix and cost rationalization
👀 What to Watch
Investors should note the successful execution of the turnaround strategy and the shift toward a more profitable, asset-light MBO model. While the company is now PBT positive, monitoring the transition to consistent net profitability (PAT) is recommended.
Indian Terrain FY26 Turnaround: PBT at ₹2.71 Cr vs ₹41.01 Cr Loss; Q4 Revenue Up 19%
Indian Terrain Fashions Limited reported a significant operational turnaround for the financial year ended March 31, 2026, posting a Profit Before Tax (PBT) of ₹2.71 Cr compared to a massive loss of ₹41.01 Cr in FY25. Annual revenue grew by 11% to ₹377.67 Cr, with Q4 FY26 showing even stronger momentum with 19% YoY growth. While the company still reported a marginal net loss of ₹4.91 Cr for the full year, this was primarily due to a deferred tax charge of ₹7.62 Cr rather than operational weakness. The company also successfully reduced its finance costs and total liabilities during the year.
Key Highlights
Full-year Revenue from Operations increased 10.8% YoY to ₹377.67 Cr from ₹340.60 Cr.
Achieved a PBT turnaround of ₹2.71 Cr in FY26 against a loss of ₹41.01 Cr in FY25.
Q4 FY26 Revenue grew 19% YoY to ₹106.53 Cr with a PBT of ₹3.54 Cr.
Annual Net Loss narrowed significantly to ₹4.91 Cr from a loss of ₹42.66 Cr in the previous year.
Finance costs reduced to ₹19.06 Cr in FY26 from ₹20.96 Cr in FY25, indicating better debt management.
👀 What to Watch
The significant reduction in losses and the shift to positive PBT indicate a strong recovery in the company's business model. Investors should watch for sustained revenue growth and the transition to net profitability in the upcoming quarters as a confirmation of a long-term trend.
Indian Terrain Q4 Revenue Up 19% YoY; FY26 Net Loss Narrows Significantly to ₹4.91 Cr
Indian Terrain Fashions reported a 19% YoY growth in Q4 revenue to ₹106.53 Cr, showing a recovery in demand. While the company posted a pre-tax profit of ₹3.54 Cr for the quarter, a high deferred tax expense of ₹4.44 Cr resulted in a marginal net loss of ₹0.90 Cr. For the full year FY26, the company significantly improved its performance, narrowing its net loss to ₹4.91 Cr from a massive ₹42.66 Cr loss in FY25. Operational efficiency improved as total expenses for the year decreased despite the rise in revenue.
Key Highlights
Revenue from operations for Q4 FY26 grew 19% YoY to ₹106.53 Cr from ₹89.53 Cr.
Full-year FY26 net loss narrowed to ₹4.91 Cr compared to a loss of ₹42.66 Cr in FY25.
Profit Before Tax (PBT) turned positive for the full year at ₹2.71 Cr vs a loss of ₹41.01 Cr in FY25.
Finance costs for the year reduced to ₹19.06 Cr from ₹20.96 Cr in the previous fiscal.
Trade receivables remain high at ₹247.51 Cr, accounting for over 50% of the total asset base.
👀 What to Watch
The company is demonstrating a clear turnaround with positive PBT and significantly reduced losses. Investors should maintain a 'Watch' stance to see if the company can achieve net profitability in the coming quarters and improve its cash conversion cycle given the high trade receivables.
Cerebra Integrated Technologies to Seek Shareholder Approval for Voluntary Insolvency (CIRP)
Cerebra Integrated Technologies has convened an Extraordinary General Meeting (EGM) on June 06, 2026, to seek shareholder approval for initiating the Corporate Insolvency Resolution Process (CIRP). The company plans to file a voluntary application under Section 10 of the IBC before the NCLT Bengaluru Bench due to its inability to service debts and ongoing defaults. This move indicates severe financial distress and a potential total restructuring or liquidation of the company. Shareholders are required to vote on this special resolution via e-voting between June 02 and June 05, 2026.
Key Highlights
EGM scheduled for June 06, 2026, to approve initiation of CIRP under Section 10 of the Insolvency and Bankruptcy Code.
Company admits to an inability to pay its debts and defaults committed in respect thereof.
Remote e-voting period is set from June 02 (9:00 AM) to June 05 (5:00 PM), 2026.
Cut-off date to determine eligible members for voting is May 29, 2026.
The Board has authorized the Chairman and CFO to file the application with the NCLT Bengaluru Bench.
👀 What to Watch
Investors should exercise extreme caution as voluntary insolvency filings typically lead to significant equity value erosion and potential suspension of trading. Recovery for equity shareholders in CIRP proceedings is usually negligible or zero.
Rain Industries Q1 2026 Commentary: Strong Demand Outlook for Carbon Segment
Rain Industries management projects a steady 3-5 year growth trajectory for CPC and CTP demand, driven by aluminum smelter restarts and higher utilization in India and North America. The company is uniquely positioned in North America, with its Canadian facility capable of supplying 100% of the region's carbon and creosote requirements if competitors exit. Integration between Carbon and Advanced Materials is increasing, focusing on higher-value products like phthalic anhydride and CARBORES to drive margin expansion. Management remains focused on passing through raw material costs while utilizing ACP technology to handle lower-grade feedstocks.
Key Highlights
Projected 3-5 year demand growth for CPC and CTP driven by global aluminum smelter restarts.
RAIN's Canadian facility can potentially supply 100% of North American carbon requirements.
Utilization-led recovery observed with existing customers in India and the US increasing offtake.
Strategic shift towards higher-value Advanced Materials like CARBORES and PETRORES to boost margins.
ACP technology deployment remains disciplined to mitigate raw material volatility and quality risks.
👀 What to Watch
Investors should focus on the company's ability to capture market share in North America and the successful ramp-up of higher-margin Advanced Materials. Monitor global aluminum utilization rates as a primary driver for RAIN's carbon segment volumes.
Rain Industries 51st AGM: FY25 Revenue at ₹16,946 Cr, ₹1 Dividend Ratified
Rain Industries concluded its 51st AGM, ratifying a ₹1 per share interim dividend and reporting FY25 consolidated revenue of ₹169,458 million. The company achieved an EBITDA of ₹22,749 million and a PAT of ₹1,178 million, reflecting sequential improvement despite volatile commodity cycles. Management highlighted a strong liquidity position of $340 million with no major debt maturities until 2028. However, the outlook remains cautious due to potential supply chain disruptions in the Carbon segment stemming from geopolitical tensions in West Asia.
Key Highlights
Consolidated FY25 revenue stood at ₹169,458 million with an EBITDA of ₹22,749 million.
Shareholders approved and ratified an interim dividend of ₹1 per equity share for the financial year 2025.
Maintained liquidity of approximately $340 million with no significant term debt maturities until 2028.
Brownfield cement expansion in Telangana remains on hold with zero expenditure incurred to date as a measure of capital prudence.
Safety performance improved significantly with the Total Recordable Incident Rate (TRIR) dropping to 0.11.
👀 What to Watch
Investors should monitor the impact of West Asian geopolitical tensions on CPC and CTP pricing, which are critical for the Carbon segment. The company's strong liquidity and deferred debt maturity profile until 2028 provide a significant buffer against near-term market volatility.
Cerebra Integrated Technologies Board Approves Initiation of Insolvency Process (CIRP)
The Board of Directors of Cerebra Integrated Technologies has approved the initiation of the Corporate Insolvency Resolution Process (CIRP) under Section 10 of the Insolvency and Bankruptcy Code, 2016. This voluntary filing indicates that the company is seeking legal intervention to resolve its debt obligations. The decision was made in a brief board meeting on May 11, 2026, and the company will now seek necessary approvals from its shareholders. This move typically precedes a significant restructuring or potential liquidation under the National Company Law Tribunal (NCLT).
Key Highlights
Board approved initiation of Corporate Insolvency Resolution Process (CIRP) under Section 10 of the IBC.
The board meeting was highly concise, commencing at 5:00 P.M. and concluding at 5:14 P.M. on May 11, 2026.
The company will seek shareholder approval for the insolvency process as per the Companies Act, 2013.
Section 10 filing implies a voluntary admission of financial distress by the corporate debtor.
👀 What to Watch
Investors should exercise extreme caution as equity value is often completely wiped out or severely diluted during the insolvency resolution process. It is advisable to monitor the NCLT admission status and consider the high risk of capital loss.
